Nicole Sonneveld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Sonneveld has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Bette Liu
National Centre for Immunisation Research and Surveillance, Kids Research, Sydney Children’s Hospitals Network, Westmead, New South Wales, Australia
2 shared publicationsKristine Macartney
National Centre for Immunisation Research and Surveillance, Kids Research, Sydney Children’s Hospitals Network, Westmead, New South Wales, Australia
2 shared publications- Aditi Dey
The Children’s Hospital at Westmead and the University of Sydney, Australia
1 shared publication Elizabeth Wilson
New South Wales Ministry of Health
1 shared publication- Frank Hudson Beard
School of Public Health, Faculty of Medicine and Health, The University of Sydney, 1 Western Avenue, Camperdown, NSW 2050, Australia
1 shared publication Joanne Jackson
National Centre for Immunisation Research and Surveillance, Australia
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (4) , e267551
Coadministered Influenza- and Pertussis-Containing Vaccines in Pregnant Women
Importance: Safety concerns are a barrier to vaccination during pregnancy. Although same-day administration of multiple vaccines may maximize uptake in pregnant women, few studies have focused on the safety of concomitant vaccination during pregnancy. Objective: To assess rates of pregnancy, birth, and neonatal outcomes following concomitant administration of influenza- and pertussis-containing vaccines in pregnant women compared with a matched control group. Design, Setting, and Participants: This population-based cohort study retrospectively analyzed linked data from perinatal and immunization registers and hospitalization data for women with singleton pregnancies in New South Wales, Australia, with estimated last menstrual period between January 1, 2021, and March 12, 2022, and their infants. Concomitant influenza and pertussis vaccination was compared with pertussis vaccination alone after 1:1 matching with replacement on vaccination date, gestation at vaccination, and maternal age. Data were analyzed between April and August 2025. Exposure: Women who received concomitant influenza- and pertussis-containing vaccine administration at 20 weeks’ gestation or later were compared with those who received pertussis vaccination alone (control group). Main Outcomes and Measures: Primary outcomes were preterm birth, stillbirth, small for gestational age, and low birth weight. Secondary outcomes were antepartum hemorrhage, postpartum hemorrhage, chorioamnionitis, preeclampsia or eclampsia, prelabor rupture of membranes, and preterm labor. Pregnancy and birth outcomes were assessed using Cox models, and neonatal outcomes were assessed using logistic regression. Results: A total of 13 918 singleton pregnancies (6959 with concomitant vaccination matched to 6959 with pertussis vaccination alone) in women with a mean (SD) maternal age at delivery of 31.7 (4.9) years were analyzed. There were 264 (3.8%) preterm births in the concomitant vaccination group and 302 (4.4%) in the matched control group. Among term live births only (6391 pairs), 565 (8.8%) infants in the concomitant vaccination group and 633 (9.9%) in the control group were small for gestational age and 107 (1.7%) infants in the concomitant vaccination group and 105 (1.6%) in the control group had low birth weight. There were 17 (0.1%) stillbirths in the total matched cohort, precluding further analysis. No difference in the rate of preterm birth (adjusted hazard ratio, 0.83; 95% CI, 0.66-1.05) or the odds of small for gestational age (adjusted odds ratio [OR], 0.87; 95% CI, 0.74-1.04) or low birth weight (adjusted OR, 0.94; 95% CI, 0.66-1.35) between the matched groups was observed. There were no differences in rates between the concomitant vaccination and control groups for the secondary outcomes. Conclusions and Relevance: In this cohort study, no association was found between concomitant influenza- and pertussis-containing vaccine administration during pregnancy and an increased rate of adverse pregnancy, birth, or neonatal outcomes compared with pertussis vaccination alone. These findings may help clinicians more confidently recommend vaccination concomitantly during pregnancy and potentially provide more opportunities to optimize uptake.
- 1 April 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (4) , e267551
Open AccessCoadministered Influenza- and Pertussis-Containing Vaccines in Pregnant Women
Importance: Safety concerns are a barrier to vaccination during pregnancy. Although same-day administration of multiple vaccines may maximize uptake in pregnant women, few studies have focused on the safety of concomitant vaccination during pregnancy. Objective: To assess rates of pregnancy, birth, and neonatal outcomes following concomitant administration of influenza- and pertussis-containing vaccines in pregnant women compared with a matched control group. Design, Setting, and Participants: This population-based cohort study retrospectively analyzed linked data from perinatal and immunization registers and hospitalization data for women with singleton pregnancies in New South Wales, Australia, with estimated last menstrual period between January 1, 2021, and March 12, 2022, and their infants. Concomitant influenza and pertussis vaccination was compared with pertussis vaccination alone after 1:1 matching with replacement on vaccination date, gestation at vaccination, and maternal age. Data were analyzed between April and August 2025. Exposure: Women who received concomitant influenza- and pertussis-containing vaccine administration at 20 weeks’ gestation or later were compared with those who received pertussis vaccination alone (control group). Main Outcomes and Measures: Primary outcomes were preterm birth, stillbirth, small for gestational age, and low birth weight. Secondary outcomes were antepartum hemorrhage, postpartum hemorrhage, chorioamnionitis, preeclampsia or eclampsia, prelabor rupture of membranes, and preterm labor. Pregnancy and birth outcomes were assessed using Cox models, and neonatal outcomes were assessed using logistic regression. Results: A total of 13 918 singleton pregnancies (6959 with concomitant vaccination matched to 6959 with pertussis vaccination alone) in women with a mean (SD) maternal age at delivery of 31.7 (4.9) years were analyzed. There were 264 (3.8%) preterm births in the concomitant vaccination group and 302 (4.4%) in the matched control group. Among term live births only (6391 pairs), 565 (8.8%) infants in the concomitant vaccination group and 633 (9.9%) in the control group were small for gestational age and 107 (1.7%) infants in the concomitant vaccination group and 105 (1.6%) in the control group had low birth weight. There were 17 (0.1%) stillbirths in the total matched cohort, precluding further analysis. No difference in the rate of preterm birth (adjusted hazard ratio, 0.83; 95% CI, 0.66-1.05) or the odds of small for gestational age (adjusted odds ratio [OR], 0.87; 95% CI, 0.74-1.04) or low birth weight (adjusted OR, 0.94; 95% CI, 0.66-1.35) between the matched groups was observed. There were no differences in rates between the concomitant vaccination and control groups for the secondary outcomes. Conclusions and Relevance: In this cohort study, no association was found between concomitant influenza- and pertussis-containing vaccine administration during pregnancy and an increased rate of adverse pregnancy, birth, or neonatal outcomes compared with pertussis vaccination alone. These findings may help clinicians more confidently recommend vaccination concomitantly during pregnancy and potentially provide more opportunities to optimize uptake.
- 25 August 2025
- Published by SAGE Publications in Health Information Management Journal
- Vol. 55 (2) , 337-347
Varicella-zoster-virus-related hospital episodes increasingly coded concurrently for varicella and zoster, Australia, 2002–2021
Background: Accurate varicella (chickenpox) and zoster (shingles)-coded hospitalisation data are important for disease surveillance and to examine the impact of immunisation programs. Varicella and zoster generally occur many years apart, with hospital episodes coded for both diseases concurrently implausible. Objective: We aimed to describe varicella-zoster virus-related hospital episodes coded for both varicella and zoster or postherpetic neuralgia (‘dual-coded’) in Australia. Method: Hospital episodes with ICD-10-AM code for varicella, zoster or postherpetic neuralgia between 2002 and 2021 were included and examined for dual-code assignment of both varicella and zoster or postherpetic neuralgia code, by principal diagnosis, age group and state/territory. Trends over time were assessed with segmented linear or negative binomial regression models. Results: The proportion of hospital episodes with principal diagnosis varicella that were dual-coded increased substantially between 2009 and 2015 ( p < 0.001; proportion p < 0.001), though was lower than observed in hospital episodes with principal diagnosis varicella. Hospital episodes with principal diagnosis post-herpetic neuralgia were rarely dual-coded. Conclusion: After 2009, hospital episodes with principal diagnosis varicella, particularly in older age groups, frequently and increasingly have an additional zoster or postherpetic neuralgia code. Increased availability of real-time polymerase chain reaction testing and inadequate documentation in hospital medical records may have contributed to this. Implications for health information management practice: As hospitalisation data are extensively used to estimate disease burden and inform public health policy, the dual-coding issues identified require further investigation and mitigation.
- 25 August 2025
- Published by SAGE Publications in Health Information Management Journal
- Vol. 55 (2) , 337-347
Varicella-zoster-virus-related hospital episodes increasingly coded concurrently for varicella and zoster, Australia, 2002–2021
Background: Accurate varicella (chickenpox) and zoster (shingles)-coded hospitalisation data are important for disease surveillance and to examine the impact of immunisation programs. Varicella and zoster generally occur many years apart, with hospital episodes coded for both diseases concurrently implausible. Objective: We aimed to describe varicella-zoster virus-related hospital episodes coded for both varicella and zoster or postherpetic neuralgia (‘dual-coded’) in Australia. Method: Hospital episodes with ICD-10-AM code for varicella, zoster or postherpetic neuralgia between 2002 and 2021 were included and examined for dual-code assignment of both varicella and zoster or postherpetic neuralgia code, by principal diagnosis, age group and state/territory. Trends over time were assessed with segmented linear or negative binomial regression models. Results: The proportion of hospital episodes with principal diagnosis varicella that were dual-coded increased substantially between 2009 and 2015 ( p < 0.001; proportion p < 0.001), though was lower than observed in hospital episodes with principal diagnosis varicella. Hospital episodes with principal diagnosis post-herpetic neuralgia were rarely dual-coded. Conclusion: After 2009, hospital episodes with principal diagnosis varicella, particularly in older age groups, frequently and increasingly have an additional zoster or postherpetic neuralgia code. Increased availability of real-time polymerase chain reaction testing and inadequate documentation in hospital medical records may have contributed to this. Implications for health information management practice: As hospitalisation data are extensively used to estimate disease burden and inform public health policy, the dual-coding issues identified require further investigation and mitigation.
- Open Access
Patterns of reporting of influenza and pertussis vaccination during pregnancy to the Australian Immunisation Register, 2022
Objectives Timely, accurate reporting of pregnancy vaccination coverage is key to evaluating pregnancy immunisation programs. We compared influenza and pertussis vaccination reporting on the New South Wales (NSW) Perinatal Data Collection (PDC) and the Australian Immunisation Register (AIR), to understand coverage, reporting, timing of vaccination and provider type. Design Retrospective population-based cohort study. Setting People giving birth at ≥20-weeks gestation (2017–2022) in the NSW PDC, linked to AIR-reported influenza and pertussis vaccinations. Main outcome measures Influenza and pertussis coverage according to 1) the PDC and 2) linked AIR records, and agreement between data sources by year (influenza: 2021–2022, pertussis: 2017–2022) and selected characteristics (2022). Description of provider type and timing for vaccinations reported to the AIR (2022). Results PDC-reported influenza and pertussis coverage peaked in 2020 (influenza: 58.8% (52,940/90,091), pertussis: 79.0% (71,169/90,091)), decreasing thereafter (influenza: 49.1% (43,744/89,112), pertussis: 77.6% (69,129/89,112) in 2022). Influenza and pertussis vaccination coverage as reported to the AIR increased from 34.7% (33,611/96,789) in 2021 to 44.8% (39,935/89,112) in 2022 and 24.4% (22,857/93,582) in 2017 to 51.6% (46,009/89,112) in 2022, respectively. Agreement between AIR and PDC improved over time, but remained suboptimal (influenza: 75.5%, pertussis: 56.6% in 2022). AIR and PDC agreement differed most by antenatal care model, particularly for pertussis vaccinations. In 2022, of pregnancy vaccinations reported to the AIR, >75% were provided in general practices. Co- administration occurred infrequently (8.8%). Conclusions Despite mandated reporting to the AIR, there was significant underreporting of pregnancy vaccinations to the AIR as compared with the NSW PDC. National collection of accurate and timely data on pregnancy vaccination coverage is needed to monitor vaccine uptake, and identify and monitor strategies to improve uptake, particularly with the new pregnancy RSV vaccine program in 2025. We identified co-administration as a potential strategy to improve influenza vaccination coverage during pregnancy.
Open AccessPatterns of reporting of influenza and pertussis vaccination during pregnancy to the Australian Immunisation Register, 2022
Objectives Timely, accurate reporting of pregnancy vaccination coverage is key to evaluating pregnancy immunisation programs. We compared influenza and pertussis vaccination reporting on the New South Wales (NSW) Perinatal Data Collection (PDC) and the Australian Immunisation Register (AIR), to understand coverage, reporting, timing of vaccination and provider type. Design Retrospective population-based cohort study. Setting People giving birth at ≥20-weeks gestation (2017–2022) in the NSW PDC, linked to AIR-reported influenza and pertussis vaccinations. Main outcome measures Influenza and pertussis coverage according to 1) the PDC and 2) linked AIR records, and agreement between data sources by year (influenza: 2021–2022, pertussis: 2017–2022) and selected characteristics (2022). Description of provider type and timing for vaccinations reported to the AIR (2022). Results PDC-reported influenza and pertussis coverage peaked in 2020 (influenza: 58.8% (52,940/90,091), pertussis: 79.0% (71,169/90,091)), decreasing thereafter (influenza: 49.1% (43,744/89,112), pertussis: 77.6% (69,129/89,112) in 2022). Influenza and pertussis vaccination coverage as reported to the AIR increased from 34.7% (33,611/96,789) in 2021 to 44.8% (39,935/89,112) in 2022 and 24.4% (22,857/93,582) in 2017 to 51.6% (46,009/89,112) in 2022, respectively. Agreement between AIR and PDC improved over time, but remained suboptimal (influenza: 75.5%, pertussis: 56.6% in 2022). AIR and PDC agreement differed most by antenatal care model, particularly for pertussis vaccinations. In 2022, of pregnancy vaccinations reported to the AIR, >75% were provided in general practices. Co- administration occurred infrequently (8.8%). Conclusions Despite mandated reporting to the AIR, there was significant underreporting of pregnancy vaccinations to the AIR as compared with the NSW PDC. National collection of accurate and timely data on pregnancy vaccination coverage is needed to monitor vaccine uptake, and identify and monitor strategies to improve uptake, particularly with the new pregnancy RSV vaccine program in 2025. We identified co-administration as a potential strategy to improve influenza vaccination coverage during pregnancy.